Merck, US gov't sign COVID therapeutic supply deal

Wednesday, 23. December 2020 14:14

Merck & Co. Inc. announced on Wednesday that the United States government will "support the development, manufacture and initial distribution of an investigational [COVID-19] biological therapeutic (CD24Fc, to be named MK-7110)" once it receives Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA).

Last month, Merck bought biopharmaceutical company OncoImmune Inc. and acquired the therapeutic in the process. Merck revealed that it will invest up to $356 million to produce and supply 60,000-100,000 doses of MK-7110 to the US authorities until June 30, 2021, in accordance with Operation Warp Speed targets.

OncoImmune said in September that MK-7110 "showed a 60% higher probability of improvement in clinical status [of hospitalized patients] compared to placebo" in an interim Phase 3 study, adding that "the risk of death or respiratory failure was reduced by more than 50%."

Related Links: Merck KGaAMerck & Co. Inc.
Breaking the News / MS